Clinical Trial Update: Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating SIM0500 as a single-agent therapy in participants with relapsed or refractory multiple myeloma; recruitment is ongoing. Sponsor: Jian…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SIM0500

Snippet

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING